默沙东
MRK90.850USD
+4.100+4.73%
交易中 （美东）报价延迟15分钟
225.98B总市值
11.87市盈率 TTM
关于 默沙东 公司
默克公司是一家研究密集型生物制药公司，致力于研究提供健康解决方案，促进人类和动物疾病的预防和治疗。其制药部门包括人类健康药品和疫苗产品。人类健康药品包括治疗和预防药物，通常通过处方出售，用于治疗人类疾病。人类健康疫苗产品包括预防性儿童、青少年和成人疫苗。动物健康部门发现、开发、制造和销售一系列兽药和疫苗产品以及健康管理解决方案和服务，用于预防、治疗和控制所有主要牲畜和伴侣动物物种的疾病。该公司还致力于开发一类新型小分子，以缺乏关键 DNA 修复蛋白 O6-甲基鸟嘌呤甲基转移酶表达的癌细胞为目标。
默沙东简介
公司代码MRK
公司名称Merck & Co Inc
上市日期Jan 01, 1941
CEOMr. Robert M. (Rob) Davis
员工数量75000
证券类型Ordinary Share
年结日Jan 01
公司地址126 East Lincoln Avenue
城市RAHWAY
上市交易所NYSE Consolidated
国家United States of America
邮编07065
电话19087404000
网址https://www.merck.com/
公司代码MRK
上市日期Jan 01, 1941
CEOMr. Robert M. (Rob) Davis
默沙东公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
其他
4.47B
28.27%
地区USD
名称
营收
占比
United States
8.84B
55.90%
Europe, Middle East and Africa
3.66B
23.15%
Latin America
859.00M
5.43%
Asia Pacific (Other than China and Japan)
785.00M
4.97%
Japan
626.00M
3.96%
其他
1.04B
6.59%
业务
地区
业务USD
名称
营收
占比
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
其他
4.47B
28.27%
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.75%
State Street Investment Management (US)
4.77%
Wellington Management Company, LLP
3.10%
Geode Capital Management, L.L.C.
2.38%
其他
73.89%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.75%
State Street Investment Management (US)
4.77%
Wellington Management Company, LLP
3.10%
Geode Capital Management, L.L.C.
2.38%
其他
73.89%
股东类型
持股股东
占比
Investment Advisor
42.33%
Investment Advisor/Hedge Fund
27.33%
Research Firm
3.24%
Pension Fund
2.47%
Bank and Trust
2.34%
Sovereign Wealth Fund
1.56%
Hedge Fund
1.38%
Insurance Company
0.71%
Family Office
0.12%
其他
18.53%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
251.75M
10.08%
+356.59K
+0.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.78M
5.72%
-4.51M
-3.06%
Jun 30, 2025
State Street Investment Management (US)
118.49M
4.74%
-2.04M
-1.69%
Jun 30, 2025
Wellington Management Company, LLP
76.86M
3.08%
-4.81M
-5.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.95M
2.36%
-704.59K
-1.18%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
53.87M
2.16%
+4.64M
+9.42%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
28.48M
1.14%
+229.47K
+0.81%
Jun 30, 2025
Fisher Investments
25.01M
1%
+567.90K
+2.32%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
22.79M
0.91%
+764.14K
+3.47%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
FT Vest DJIA Dogs 10 Target Income ETF
7.58%
VanEck Pharmaceutical ETF
7.44%
First Trust NASDAQ Pharmaceuticals ETF
7.32%
Coastal Compass 100 ETF
7.15%
Invesco Dow Jones Industrial Average Dividend ETF
6.85%
iShares ESG Aware MSCI USA Value ETF
5.44%
First Trust Morningstar Dividend Leaders Index Fund
5.03%
Franklin Income Focus ETF
4.92%
Invesco Pharmaceuticals ETF
4.84%
VanEck Morningstar Wide Moat Value ETF
4.6%
查看更多
FT Vest DJIA Dogs 10 Target Income ETF
占比7.58%
VanEck Pharmaceutical ETF
占比7.44%
First Trust NASDAQ Pharmaceuticals ETF
占比7.32%
Coastal Compass 100 ETF
占比7.15%
Invesco Dow Jones Industrial Average Dividend ETF
占比6.85%
iShares ESG Aware MSCI USA Value ETF
占比5.44%
First Trust Morningstar Dividend Leaders Index Fund
占比5.03%
Franklin Income Focus ETF
占比4.92%
Invesco Pharmaceuticals ETF
占比4.84%
VanEck Morningstar Wide Moat Value ETF
占比4.6%
分红派息
近5年累计派现
35.12B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
